Improvements in Time-Sensitive Stroke Care and Alteplase Administration: The Iranian Comprehensive Code Stroke Management Program (ICSM Phase III).
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 41778312.
- Also identified by DOI 10.1161/STROKEAHA.125.053785.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Timely management of acute stroke in the emergency medical services setting is critical. Systemic challenges in this phase include the absence of evidence-based standards, inconsistent protocols, and coordination delays. This study aimed to implement and evaluate an updated national stroke protocol in northern Iran. This quasi-experimental study evaluated the Iranian Comprehensive Code Stroke Management Program. The intervention group (Babol emergency medical services, n=248) received a multi-faceted empowerment program, while the control group (Mazandaran emergency medical services, n=900) received standard training. Patients' level outcomes were assessed on prehospital time, monthly intravenous alteplase counts, and administration rates before (March-September 2023) and after the intervention (March-September 2024). Of 1131 suspected stroke codes, 400 (35%) were hospital-confirmed. The intervention significantly reduced most prehospital time intervals (except transport time) and increased the rate of intravenous alteplase administration per hospital-confirmed stroke code from 13.94% preintervention to 39.49% postintervention (absolute increase +25.55%±19.17; <i>P</i><0.001). Additionally, the mean monthly number of alteplase administrations showed an increasing trend (+4.00±4.64; <i>P</i>=0.07). Conversely, the control group exhibited a significant decrease in the mean number of monthly alteplase administrations (-0.72±0.57; <i>P</i>=0.04) and a nonsignificant reduction in the administration rate (-1.49 percentage points; SD ±6.47; <i>P</i>=0.69). Implementing the updated protocol was associated with significant reductions in critical time intervals and a near-tripling of the intravenous alteplase administration rate in the intervention group. National evaluation should include long-term functional outcomes to confirm effectiveness and establish its value as a model.